New report examines Epstein s longstanding relationship with Les Wexner
Sex predator served as financial advisor to the billionaire founder of The Limited
Epstein forced out Wexner s money manager Harold Levin and left him destitute
Levin tells how Wexner ignored his warnings to stay away from Epstein
Epstein seemed to have Wexner in his thrall in the odd relationship
Wexner claims that he was conned by Epstein and accused him of stealing funds
Article content
Sex monster Jeffrey Epstein plotted his seduction of the billionaire founder of Victoria’s Secret with military precision, according to a new report.
Vanity Fair reports that hedge fund manager Epstein weaseled his way into the lingerie giant’s inner circle by way of pal Robert Meister.
We apologize, but this video has failed to load.
Try refreshing your browser, or How bulls t artist Jeffrey Epstein seduced Victoria s Secret CEO Back to video
“He was a great bulls t artist,” Meister told the glossy mag, adding that he believes Epstein befriended him in order to gain access to his billionaire pals.
Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of Biopharmaceutical Industry Experience Selexis SA, a JSR Life Sciences company, has named
GENEVA (BUSINESS WIRE) Jun 1, 2021
Selexis SA, a JSR Life Sciences company, has named seasoned business development executive Roland Hoffmann-Hecht, PhD, as its new chief business officer. As a member of the companyâs executive leadership team, Dr. Hoffmann-Hecht will be responsible for all corporate and business development activities and will report directly to Selexis Chief Executive Officer Dirk Lange.
(Photo: Business Wire)
âWe are fortunate to welcome Roland to our executive leadership team given his expansive career in contract development and manufacturing organizations (CDMOs) serving the biopharmaceuticals industry and demonstrated success building valuable relationships with partners,â said Mr. Lange. âHis highly relevant skills and experience, coupled with his scientific and industry knowledge, will be invaluable to Selexis as we bolster our leading position in cell line development and ensure the continued success of our âGene-to-GMP in 9 Mon